Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children

NCT05448807
completedphase_4

Reversing the Effects of 0.5% Bupivacaine

NCT02995291
completedphase_4

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

NCT01474382

Clinical Trials (3)

Showing 3 of 3 trials
NCT05448807Phase 3

Effectiveness of Phentolamine Mesylate as a Reversing Agent for Local Anesthesia in Children

Recruiting
NCT02995291Phase 4

Reversing the Effects of 0.5% Bupivacaine

Completed
NCT01474382Phase 4

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3